Item 2.02. Results of Operations and Financial Condition.

On May 12, 2022, Matinas BioPharma Holdings, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2022. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 7.01. Regulation FD Disclosure.

The Company updated its corporate presentation (the "Corporate Presentation") which it intends to use at various conferences and investor meetings. The Corporate Presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.





Exhibit No.   Description

99.1            Press Release, dated May 12, 2022.
99.2            Corporate Presentation, dated May 12, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)




-2-

© Edgar Online, source Glimpses